½ÃÀ庸°í¼­
»óǰÄÚµå
1654364

dz¼±ÆÇ¸·¼ºÇü¼ú ±â±â ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)

Balloon Valvuloplasty Devices Market Size, Share & Trends Analysis Report By Application (Aortic Valve Stenosis, Pulmonary Valve Stenosis), By End-use, By Region, And Segment Forecasts, 2025 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 100 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

dz¼±ÆÇ¸·¼ºÇü¼ú ±â±â ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°èÀÇ Ç³¼±ÆÇ¸·¼ºÇü¼ú ±â±â ½ÃÀå ±Ô¸ð´Â 2025-2030³â ¿¬Æò±Õ 4.1%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» º¸À̰í, 2030³â±îÁö 30¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÉÀåÆÇ¸·ÁõÀ» Æ÷ÇÔÇÑ ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡, ½ÅÁ¦Ç° Ãâ½Ã, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ÷´Ü ÀÇ·á ÀÎÇÁ¶ó°¡ ºÏ¹ÌÀÇ Ç³¼± ÆÇ¸· ¼ºÇü±â ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ·ù¸¶Æ¼½º¼º ½ÉÀ庴(RHD)Àº ·ù¸¶Æ¼½º ¿­·Î ÀÎÇÑ ½ÉÀå ÆÇ¸· ¼Õ»óÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ½É°¢ÇÑ ½ÉÇ÷°ü ÁúȯÀÔ´Ï´Ù.

¹Ì±¹½ÉÀåÇùȸ°¡ 2024³â 4¿ù¿¡ ¹ßÇ¥ÇÑ º¸°í¼­¿¡ µû¸£¸é ½ÉÀåÆÇ¸·Áõ(VHD)Àº ¹Ì±¹¿¡¼­ °¡Àå ³Î¸® ÆÛÁ®ÀÖ´Â °Ç°­ »óÅ Áß Çϳª·Î ¼ºÀÎ Àα¸ÀÇ ¾à 2.5%°¡ ¾Î°í ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ´ëµ¿¸ÆÆÇ¸·Áúȯ°ú ½Â¸ðÆÇ¸·ÁúȯÀº VHD Áß °¡Àå ¸¹ÀÌ Áø´ÜµÇ´Â ÁúȯÀ¸·Î, dz¼±ÆÇ¸·¼ºÇü¼ú°ú °°Àº È¿°úÀûÀÎ Ä¡·á ¿É¼ÇÀÌ ÀÌ Áõ°¡ÇÏ´Â °Ç°­ ¹®Á¦¸¦ ÇØ°áÇÏ´Â µ¥ ÇʼöÀûÀ̶ó´Â Á¡À» ´õ¿í °­Á¶Çϰí ÀÖ½À´Ï´Ù.

ÀÎ½Ä °³¼±°ú °ËÁø ÇÁ·Î±×·¥ÀÌ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2024³â 9¿ù ¼¼°è ÇÏÆ® Çãºê´Â 2040³â±îÁö 2¹è, 2060³â±îÁö 3¹è·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ½ÉÀåÆÇ¸·Áõ À¯º´·ü Áõ°¡¸¦ °­Á¶ÇÏ´Â Ä·ÆäÀÎÀ» ½ÃÀÛÇß½À´Ï´Ù. ÀÌ Ä·ÆäÀÎÀº Á¤±âÀûÀÎ °Ç°­°ËÁøÀ» ÅëÇÑ Á¶±â ¹ß°ßÀÇ Á߿伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù. ÀÌ ´Üü´Â dz¼±ÆÇ¸·¼ºÇü¼ú°ú °°Àº Áõ»ó°ú °¡´ÉÇÑ Ä¡·á¹ý¿¡ ´ëÇØ ´ëÁß¿¡°Ô ¾Ë¸®´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù.

dz¼±ÆÇ¸·¼ºÇü¼ú ±â±â ½ÃÀå : ºÐ¼® °³¿ä

  • ¿ëµµº°·Î´Â ´ëµ¿¸ÆÆÇ¸· ÇùÂøÁõ ºÐ¾ß°¡ 2024³â 64.42% ÀÌ»óÀÇ ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. Àü ¼¼°è ½ÉÀå ÆÇ¸· Áúȯ ¹ßº´·ü Áõ°¡¿Í ±â¼ú ¹ßÀüÀÌ ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.
  • ÃÖÁ¾ ¿ëµµº°·Î´Â º´¿ø ºÎ¹®ÀÌ 2024³â 57.4%·Î ÃÖ´ëÀÇ ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. Àü ¼¼°è¿¡¼­ ½ÉÀå ÆÇ¸· ÁúȯÀÇ ¹ßº´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó º´¿ø³» ȯÀÚ Ä¡·á¸¦ È¿°úÀûÀ¸·Î °ü¸®Çϱâ À§ÇÑ Ã·´Ü ¼Ö·ç¼ÇÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù.
  • ºÏ¹Ì´Â ½ÉÀåÆÇ¸·ÁõÀ» Æ÷ÇÔÇÑ ½ÉÇ÷°ü Áúȯ ȯÀÚ ¼ö Áõ°¡·Î ÀÎÇØ 2024³â 41.1%ÀÇ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. Á¦Ç° Ãâ½Ã, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ÷´Ü ÀÇ·á ÀÎÇÁ¶ó°¡ dz¼± ÆÇ¸· Çü¼º Àåºñ¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ºÐ¼® ¹æ¹ý¡¤¹üÀ§

Á¦2Àå °³¿ä

Á¦3Àå dz¼±ÆÇ¸·¼ºÇü¼ú ±â±â ½ÃÀå : º¯µ¿ ¿äÀΡ¤°æÇ⡤¹üÀ§

  • ½ÃÀå ¿¬°ü Àü¸Á
    • ¸ð½ÃÀå Àü¸Á
    • °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • dz¼±ÆÇ¸·¼ºÇü¼ú ±â±â ½ÃÀå : ºÐ¼® Åø
    • ¾÷°è ºÐ¼® : PorterÀÇ »ê¾÷ ºÐ¼®
    • PESTEL ºÐ¼®

Á¦4Àå dz¼±ÆÇ¸·¼ºÇü¼ú ±â±â ½ÃÀå : ¿ëµµº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • dz¼±ÆÇ¸·¼ºÇü¼ú ±â±â ½ÃÀå : ¿ëµµº° ´ë½Ãº¸µå
  • dz¼±ÆÇ¸·¼ºÇü¼ú ±â±â ½ÃÀå : ¿ëµµº° º¯µ¿ ºÐ¼®
  • dz¼±ÆÇ¸·¼ºÇü¼ú ±â±â ½ÃÀå : ½ÃÀå ±Ô¸ð ¿¹Ãø°ú µ¿Ç⠺м®, ¿ëµµº°(2018-2030³â)
  • ´ëµ¿¸ÆÆÇ ÇùÂøÁõ
  • Æóµ¿¸ÆÆÇ ÇùÂøÁõ

Á¦5Àå dz¼±ÆÇ¸·¼ºÇü¼ú ±â±â ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • dz¼±ÆÇ¸·¼ºÇü¼ú ±â±â ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ´ë½Ãº¸µå
  • dz¼±ÆÇ¸·¼ºÇü¼ú ±â±â ½ÃÀå : ÃÖÁ¾ ¿ëµµº° º¯µ¿ ºÐ¼®
  • dz¼±ÆÇ¸·¼ºÇü¼ú ±â±â ½ÃÀå : ½ÃÀå ±Ô¸ð ¿¹Ãø°ú µ¿Ç⠺м®, ÃÖÁ¾ ¿ëµµº°(2018-2030³â)
  • º´¿ø
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ(ASC)
  • ½ÉÀå Ä«Å×ÅÍ °Ë»ç½Ç

Á¦6Àå dz¼±ÆÇ¸·¼ºÇü¼ú ±â±â ½ÃÀå : Áö¿ªº° ÃßÁ¤°ú µ¿Ç⠺м®(¿ëµµº°¡¤ÃÖÁ¾ ¿ëµµº°)

  • ¼¼°èÀÇ Ç³¼±ÆÇ¸·¼ºÇü¼ú ±â±â ½ÃÀå : Áö¿ªº° ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð ¿¹Ãø°ú µ¿Ç⠺м®(2018-2030³â)
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
    • µ§¸¶Å©
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • ű¹
    • Çѱ¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • Äí¿þÀÌÆ®

Á¦7Àå °æÀï ±¸µµ

  • ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м® : ÁÖ¿ä Á¦Á¶¾÷üº°
  • ±â¾÷/°æÀïÀÇ ºÐ·ù
  • º¥´õ ±¸µµ
    • ÁÖ¿ä ÆÇ¸Å ´ë¸®Á¡ ¹× ä³Î ÆÄÆ®³Ê ¸®½ºÆ®
    • Key customers
    • Key company market share analysis, 2024
    • B. Braun Interventional Systems, Inc.
    • BD
    • Edwards Lifesciences Corporation
    • Boston Scientific Corporation
    • Getinge
    • TORAY INTERNATIONAL AMERICA, INC.
    • Stryker
    • BrosMed Medical Co., Ltd.
    • Medtronic
    • Terumo Corporation
    • Koninklijke Philips NV
KSA 25.03.19

Balloon Valvuloplasty Devices Market Growth & Trends:

The global balloon valvuloplasty devices market size is expected to reach USD 3.02 billion by 2030, registering a CAGR of 4.1% from 2025 to 2030, according to a new report by Grand View Research, Inc.The increasing prevalence of cardiovascular diseases, including valvular heart diseases, new product launches, regulatory approvals, and advanced healthcare infrastructure, drives the demand for balloon valvuloplasty devices in North America. Rheumatic heart disease (RHD) is a serious cardiovascular condition that arises from damage to the heart valves due to rheumatic fever.

According to a report published by the American Heart Association in April 2024, valvular heart disease (VHD) is among the most prevalent health conditions in the U.S., affecting about 2.5% of the adult population. Aortic and mitral valve diseases are the most diagnosed types of VHD, further emphasizing the critical need for effective treatment options like balloon valvuloplasty devices to address this growing health concern.

Increasing awareness and screening programs fuel the market's growth. For instance, in September 2024, the Global Heart Hub initiated campaigns highlighting the rising prevalence of heart valve disease, which is expected to double by 2040 and triple by 2060. These efforts stress the critical role of early detection through regular medical check-ups. The organization aims to inform the public about the symptoms and available treatments, such as balloon valvuloplasty.

Balloon Valvuloplasty Devices Market Report Highlights:

  • Based on application, the aortic valve stenosis segment held the largest share, over 64.42%, in 2024. The global rise in the incidence of valvular heart diseases and technological advancements drive the segment's growth
  • Based on end use, the hospital segment held the largest revenue share at 57.4% in 2024. The rising incidence of valvular heart diseases globally necessitates advanced solutions within hospitals to manage patient care effectively
  • North America dominated the market with a share of 41.1% in 2024, owing to the rising cases of cardiovascular diseases, including valvular heart diseases. Product launches, regulatory approvals, and advanced healthcare infrastructure drive the demand for balloon valvuloplasty devices

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Application
    • 1.2.2. End use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecast timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity price analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Application Segment
    • 2.2.2. End use Segment
    • 2.2.3. Regional Outlook
  • 2.3. Competitive Insights

Chapter 3. Global Balloon Valvuloplasty Devices Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of valvular heart diseases
      • 3.2.1.2. Technological advancements in balloon valvuloplasty devices
      • 3.2.1.3. Increasing awareness and screening programs
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost associated with the devices and procedures
      • 3.2.2.2. Regulatory compliance
  • 3.3. Balloon Valvuloplasty Devices Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Balloon Valvuloplasty Devices Market: Application Estimates & Trend Analysis

  • 4.1. Balloon Valvuloplasty Devices Market: Application Dashboard
  • 4.2. Balloon Valvuloplasty Devices Market: Application Movement Analysis
  • 4.3. Balloon Valvuloplasty Devices Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 4.4. Aortic Valve Stenosis
    • 4.4.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 4.5. Pulmonary Valve Stenosis
    • 4.5.1. Market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 5. Balloon Valvuloplasty Devices Market: End Use Estimates & Trend Analysis

  • 5.1. Balloon Valvuloplasty Devices Market: End Use Dashboard
  • 5.2. Balloon Valvuloplasty Devices Market: End Use Movement Analysis
  • 5.3. Balloon Valvuloplasty Devices Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 5.4. Hospitals
    • 5.4.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 5.5. Ambulatory Surgical Centers (ASCs)
    • 5.5.1. Market estimates and forecasts 2018 to 2030, (USD Million)
  • 5.6. Cardiac Catheterization Labs
    • 5.6.1. Market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 6. Balloon Valvuloplasty Devices Market: Regional Estimates & Trend Analysis by Country, Application, & End use

  • 6.1. Global Balloon Valvuloplasty Devices Market: Regional Dashboard
  • 6.2. Market Size & Forecasts Trend Analysis, 2018 to 2030
  • 6.3. North America
    • 6.3.1. Market Estimates and Forecasts 2018 to 2030, (USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. U.S. market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Canada market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.3.4. Mexico
      • 6.3.4.1. Key country dynamics
      • 6.3.4.2. Regulatory framework/ reimbursement structure
      • 6.3.4.3. Competitive scenario
      • 6.3.4.4. Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. Market Estimates and Forecasts 2018 to 2030, (USD Million)
    • 6.4.2. UK
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. UK market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.4.3. Germany
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. Germany market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.4.4. France
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. France market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.4.5. Italy
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Italy market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.4.6. Spain
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Spain market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.8. Norway
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Norway market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.9. Denmark
      • 6.4.9.1. Key country dynamics
      • 6.4.9.2. Regulatory framework/ reimbursement structure
      • 6.4.9.3. Competitive scenario
      • 6.4.9.4. Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Market Estimates and Forecasts 2018 to 2030, (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Japan
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. Japan market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. India
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. India market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Australia
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. Australia market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. South Korea
      • 6.5.7.1. Key country dynamics
      • 6.5.7.2. Regulatory framework/ reimbursement structure
      • 6.5.7.3. Competitive scenario
      • 6.5.7.4. South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Market Estimates and Forecasts 2018 to 2030, (USD Million)
    • 6.6.2. Brazil
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. Market Estimates and Forecasts 2018 to 2030, (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. South Africa
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.7.4. UAE
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. UAE market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.7.5. Kuwait
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/ reimbursement structure
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Manufacturers
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2024
    • 7.3.4. B. Braun Interventional Systems, Inc.
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. BD
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Edwards Lifesciences Corporation
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Boston Scientific Corporation
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Getinge
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. TORAY INTERNATIONAL AMERICA, INC.
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Stryker
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. BrosMed Medical Co., Ltd.
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Medtronic
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. Terumo Corporation
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Product benchmarking
      • 7.3.13.4. Strategic initiatives
    • 7.3.14. Koninklijke Philips N.V.
      • 7.3.14.1. Company overview
      • 7.3.14.2. Financial performance
      • 7.3.14.3. Product benchmarking
      • 7.3.14.4. Strategic initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦